Atom | Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Due Dates: April 2, 2025 (Letter of Intent) | May 2, 2025 (Full Application)

Funding Amounts: R61: up to $300,000 direct costs/year (2 years) | R33: up to $750,000 direct costs/year (3 years) | Up to 5 years total

Summary: Supports milestone-driven, phased research to develop broad-spectrum therapeutics that treat and reverse intoxication by multiple botulinum neurotoxin (BoNT) serotypes.

Key Information: Clinical trials are not allowed; only U.S.-based organizations and components are eligible.

Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Sign in to see full grant listing